Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis
AF Ozaki, AS Choi, QT Le, DT Ko, JK Han… - … Quality and Outcomes, 2020 - Am Heart Assoc
Background: Stroke reduction with direct oral anticoagulants (DOACs) in atrial fibrillation
(AF) is dependent on adherence and persistence in the real-world setting. Individual study …
(AF) is dependent on adherence and persistence in the real-world setting. Individual study …
Risk of major gastrointestinal bleeding with new vs conventional oral anticoagulants: a systematic review and meta-analysis
ZC Gu, AH Wei, C Zhang, XH Wang, L Zhang… - Clinical …, 2020 - Elsevier
Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs …
K Chan, S Nam, B Evans, C de Oliveira, A Chambers… - BMJ open, 2020 - bmjopen.bmj.com
Background Oncology therapy is becoming increasingly more expensive and challenging
the affordability and sustainability of drug programmes around the world. When new drugs …
the affordability and sustainability of drug programmes around the world. When new drugs …
Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational …
LM Paschke, K Klimke, A Altiner, D von Stillfried… - BMC medicine, 2020 - Springer
Abstract Background Direct oral anticoagulants (DOACs) are not only increasingly being
used for the initial stroke prevention therapy but progressively also substitute vitamin K …
used for the initial stroke prevention therapy but progressively also substitute vitamin K …
Effectiveness and safety of off-label dosing of non–vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients
KN Lee, JI Choi, KY Boo, DY Kim, YG Kim, SK Oh… - Scientific reports, 2020 - nature.com
Non–vitamin K antagonist anticoagulants (NOACs) have been used to prevent
thromboembolism in patients with atrial fibrillation (AF) and shown favorable clinical …
thromboembolism in patients with atrial fibrillation (AF) and shown favorable clinical …
[HTML][HTML] A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and …
H Kim, YS Lee, TH Kim, MJ Cha, JM Lee… - The Korean Journal …, 2020 - ncbi.nlm.nih.gov
Methods In a prospective observational registry (COmparison study of Drugs for symptom
control and complication prEvention of Atrial Fibrillation [CODE-AF] registry), 7,013 patients …
control and complication prEvention of Atrial Fibrillation [CODE-AF] registry), 7,013 patients …
Bleeding risk in nonvalvular atrial fibrillation patients receiving direct oral anticoagulants and warfarin: a systematic review and meta-analysis of observational studies
YP Wang, R Kehar, A Iansavitchene… - TH Open, 2020 - thieme-connect.com
Introduction In randomized trials in atrial fibrillation (AF) patients on direct oral
anticoagulants (DOACs) have a lower risk of bleeding compared with warfarin. However …
anticoagulants (DOACs) have a lower risk of bleeding compared with warfarin. However …
Persistence with anticoagulation for atrial fibrillation: report from the GLORIA-AF phase III 1-year follow-up
M Kozieł, M Mazurek, C Teutsch, HC Diener… - Journal of Clinical …, 2020 - mdpi.com
Background: We aimed to assess the extent to which drug persistence is better with non-
vitamin K antagonist oral anticoagulants (NOACs) than vitamin K antagonists (VKAs) in atrial …
vitamin K antagonist oral anticoagulants (NOACs) than vitamin K antagonists (VKAs) in atrial …
Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3‐year period population‐based prospective cohort study
J Bouget, F Balusson, M Maignan… - British Journal of …, 2020 - Wiley Online Library
Aims The objective was to compare major bleeding risk of direct oral anticoagulants
(DOACs; per type and dose) with vitamin K antagonists (VKAs), irrespective of indication …
(DOACs; per type and dose) with vitamin K antagonists (VKAs), irrespective of indication …
Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up
M Corrochano, B Jiménez, J Millón, I Gich… - BMC cardiovascular …, 2020 - Springer
Background Patient self-management (PSM) of vitamin K antagonists (VKA) seems a very
promising model of care for oral anticoagulation in terms of efficacy and safety. In …
promising model of care for oral anticoagulation in terms of efficacy and safety. In …